Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
04:30pm, Monday, 16'th Mar 2026
Basel, 16 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that an expansion of its global AI infrastructure, deploying a large-scale AI factory powered by a full stack of the latest-ge
The Elecsys ApoE4 test is the first CE marked in-vitro diagnostic immunoassay to identify individuals carrying the ApoE4 genetic variant using a simple blood sample. The test offers a fast, reliable a
Harbor Health Care ETF Q4 2025 Portfolio Review
08:18am, Wednesday, 11'th Mar 2026
Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly deliv
Assemblée générale annuelle 2026 de Roche
09:15am, Tuesday, 10'th Mar 2026
Adoption de toutes les propositions du Conseil d'administration Réélection de Severin Schwan à la présidence du Conseil d'administration; confirmation de tous les autres membres du Conseil d'admin
Roche Generalversammlung 2026
09:15am, Tuesday, 10'th Mar 2026
Alle Anträge des Verwaltungsrates genehmigt Severin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Verwaltungsrätinnen und Verwaltungsräte bestätigt 3
Roche Annual General Meeting 2026
09:15am, Tuesday, 10'th Mar 2026
Basel, 10 March 2026 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting. The 594 shareholders i
Glooko to Expand EMEA CGM Connectivity with Roche Accu-Chek® SmartGuide Integration
08:00am, Tuesday, 10'th Mar 2026
GOTHENBURG, Sweden--(BUSINESS WIRE)--Glooko, Inc., a globally integrated digital healthcare company focused on helping healthcare systems solve the growing challenges of glycemic safety and diabetes m
Strait of Hormuz will partially reopen in 2-3 weeks: David Roche
04:21am, Tuesday, 10'th Mar 2026
Quantum Strategy' David Roche says he expects oil reserves can sufficiently support world demand, and that the 'world won't run out of oil'. He also explains why he believes Iran can't afford to escal
Roche Holding AG (RHHBY) Discusses Phase III Study Results and Updates on Immunology Kidney Pipeline Transcript
06:47pm, Monday, 09'th Mar 2026
Roche Holding AG (RHHBY) Discusses Phase III Study Results and Updates on Immunology Kidney Pipeline Transcript
Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study
11:25am, Monday, 09'th Mar 2026
RHHBY reports that giredestrant plus palbociclib misses the main PFS goal in a phase III first-line breast cancer study, though the combo shows a numerical improvement.
Roche Shares Drop Up to 7.5% After Breast Cancer Pill Misses Trial Goal
09:21am, Monday, 09'th Mar 2026
Roche (RHHBY) shares came under pressure in early Zurich trading after the Swiss drugmaker reported that its experimental breast-cancer pill giredestrant failed
Roche shares drop as oral breast cancer drug fails in trial
04:55am, Monday, 09'th Mar 2026
Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate giredestrant against a common form of breast cancer can help newly diagnose
Roche Breast-Cancer Treatment Falls Short of Primary Goal in Late-Stage Study
02:36am, Monday, 09'th Mar 2026
The combination of Roche's investigational drug, giredestrant, with Pfizer's Ibrance didn't lead to a statistically significant improvement among patients with advanced breast cancer.
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
02:10am, Monday, 09'th Mar 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from the Phase III persevERA Breast Cancer study evaluating i
Basel, 9 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination with palbocicli
